Abstract 66P
Background
The phenomenon of intratumoral morphological heterogeneity is associated with both the progression of the disease and chemosensitivity and chemoresistance. However, there are very few data about the microenvironment heterogeneity near morphological structures in breast cancer patients of various molecular subtypes. This phenomenon may underlie the failure of tumor-infiltration lymphocytes as a prognostic factor in luminal forms of breast cancer.
Methods
152 patients with IC NST (T1–3N0–2M0) aged 29 to 75 years were enrolled in the study. The molecular subtype was determined using immunohistochemical analysis of the expression of estrogen and progesterone receptors, Ki-67 and Her2/neu. TILs were assessed in accordance with the recommendations of the International TILs Working Group
Results
It was shown that TILs near the various morphological structures is heterogeneous only in luminal Her2-negative patients. In addition, was found that the development of distant metastases and worse metastatic-free survival in this cohort of patients is associated with a high (more than 5%) TILs near solid structures and also depended on Ki-67 level.
Conclusions
TILs near solid structures is a potential prognostic factor for the development of distant metastasis in the luminal Her2-negative and Ki-67 level less 20% subtype of IC NST. The study was supported by the Russian Science Foundation (grant #20-75-10033).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
the Russian Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session